SIPP Industries Announces Strategic R&D Agreement with Calypso Pharmaceuticals to Develop Nano-Emulsified Topical Targeting Melanoma
Peptide P16, a synthetic, cell-penetrating peptide derived from the melanoma suppressor P16, has demonstrated promising results in selectively killing melanoma cells while sparing normal cells.
- Peptide P16, a synthetic, cell-penetrating peptide derived from the melanoma suppressor P16, has demonstrated promising results in selectively killing melanoma cells while sparing normal cells.
- Utilizing Peptide P16 in nano emulsions for melanoma treatment offers a promising strategy to enhance apoptosis and effectively target cancer cells.
- Calypso Pharmaceuticals' nanotechnology produces particle sizes ranging from 1 nm to 600 nm and can deliver therapeutic agents like P16 peptides more efficiently to tumor sites.
- "By combining AVEINA’s cutting-edge topical formulations with Calypso’s pharmaceutical expertise and nanotechnology, we are poised to develop a highly effective topical treatment that could revolutionize melanoma therapy.